VERACYTE, INC. 8-K

What Happened

• Veracyte, Inc. (VCYT) filed an 8-K (Item 5.02) on March 16, 2026 announcing that Dr. Kevin Haas, age 40, will join the company as Chief Development and Technology Officer effective March 24, 2026. Dr. Haas most recently served as Chief Technology Officer of Myriad Genetics (NASDAQ: MYGN) since February 2021 and previously held senior technology and bioinformatics roles at Myriad Women’s Health. He holds a B.S. in Chemical Engineering from the University of Wisconsin–Madison and a Ph.D. in Chemical Engineering from UC Berkeley.

Key Details

• Start date: March 24, 2026; announcement filed March 16, 2026; offer letter dated March 13, 2026.
• Base salary: $500,000 per year.
• Annual bonus: Eligible for the company’s performance-based cash bonus with a target equal to 55% of eligible annual earnings (2026 bonus to be prorated).
• Equity: Target restricted stock units (RSUs) worth $1,500,000 vesting over four years, plus performance-based RSUs with a $1,500,000 target value contingent on performance goals and continued service. Awards under the 2023 Equity Incentive Plan.
• Additional: Company will enter into the standard executive indemnification agreement; filing states no related-party arrangements, family relationships, or reportable transactions under Item 404.

Why It Matters

• This is a senior technology and development hire for Veracyte, signaling reinforcement of the company’s product development and technology leadership. The compensation package combines cash, time‑based equity and performance‑based equity, aligning Dr. Haas’s incentives with company performance and shareholder outcomes. Investors should note the material elements (salary, bonus target, and $3.0M total target equity) as potential near‑term dilution and long‑term retention incentives; the Offer Letter will be filed as an exhibit to Veracyte’s next Form 10-Q for the quarter ending March 31, 2026.